Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial

Article2018

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Masatoshi Kudo, Richard S. Finn, Shukui Qin, Kwang–Hyub Han, Kenji Ikeda, Fabio Piscaglia, Ari David Baron, Joong‐Won Park, Guohong Han, Jacek Jassem, Jean Frédéric Blanc, Arndt Vogel, Д. В. Комов, T.R. Jeffry Evans, Carlos López, Corina E. Dutcus, Matthew Guo, Kenichi Saito, Silvija Kraljevic, Toshiyuki Tamai, Min Ren, Ann‐Lii Cheng

Article2025

Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial

Thomas Yau, Peter R. Galle, Thomas Decaens, Bruno Sangro, Shukui Qin, Leonardo Gomes da Fonseca, Hatim Karachiwala, Jean–Frédéric Blanc, Joong‐Won Park, Edward Gane, Matthias Pinter, Ana Matilla Peña, Masafumi Ikeda, David Tai, Armando Santoro, Gonzalo Pizarro, Chang‐Fang Chiu, Michael Schenker, Aiwu Ruth He, Hong Jae Chon, Joanna Wójcik-Tomaszewska, Gontran Verset,

Article2021

Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial

Peter R. Galle, Richard S. Finn, Shukui Qin, Masafumi Ikeda, Andrew X. Zhu, Tae‐You Kim, Masatoshi Kudo, В. В. Бредер, Philippe Merle, Ahmed O. Kaseb, Daneng Li, Sohail Mulla, Wendy Verret, Derek-Zhen Xu, Sairy Hernandez, Beiying Ding, Juan Liu, Chen Huang, Ho Yeong Lim, Ann‐Lii Cheng, Michel Ducreux

Article2014

A multicenter, open-label, phase 3 trial to compare the efficacy and safety of lenvatinib (E7080) versus sorafenib in first-line treatment of subjects with unresectable hepatocellular carcinoma.

Richard S. Finn, Ann‐Lii Cheng, Kenji Ikeda, Masatoshi Kudo, Toshiyuki Tamai, Corina E. Dutcus, Steven Younger, Kwang–Hyub Han, Shukui Qin, Éric Raymond

Article2021

Nivolumab Versus Sorafenib Treatment in Advanced Hepatocellular Carcinoma (CheckMate 459): A Randomised, Multicentre, Open-Label, Phase 3 Trial

Thomas Yau, Joong‐Won Park, Richard S. Finn, Ann‐Lii Cheng, Philippe Mathurin, Julien Edeline, Masatoshi Kudo, James J. Harding, Philippe Merle, Olivier Rosmorduc, Lucjan Wyrwicz, Eckart Schott, Su Pin Choo, Robin Kate Kelley, Wolfgang Sieghart, Éric Assenat, Renata Zaucha, Junji Furuse, Ghassan K. Abou‐Alfa, Anthony B. El-Khoueiry, Ignacio Melero, Damir Begic,

Discussion(0)

Related publications